• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Hum Vaccin Immunother . Activation of IgG antibody and mucosal T cell responses to MERS-CoV in human nasopharynx-associated lymphoid tissue by a ChAdO

tetano

Editor, Senior Moderator
Hum Vaccin Immunother

. 2026 Dec;22(1):2756059.
doi: 10.1080/21645515.2026.2756059. Epub 2026 Nov 9.

Activation of IgG antibody and mucosal T cell responses to MERS-CoV in human nasopharynx-associated lymphoid tissue by a ChAdOx1 vectored vaccine candidate and inactivated MERS-CoV​


Khalid J Shrwani 1 2 , Ravi Sharma 3 , Madhankumar Krishnan 3 , Samuel Leong 4 , Teresa Lambe 5 , Sarah C Gilbert 5 , Nigel Cunliffe 1 , Qibo Zhang 1 6

Affiliations Expand


Abstract​


Middle East respiratory syndrome coronavirus (MERS-CoV) causes serious infection in humans with up to 40% mortality. As MERS-CoV infects humans via nasopharyngeal mucosa, local mucosal immunization may provide an effective vaccination strategy. Nasopharynx-associated lymphoid tissues (NALT, comprising adenotonsillar tissues) are immune induction sites for intranasal vaccines. We studied the capacity of a viral vectored MERS candidate vaccine (ChAdOx1 MERS) and inactivated MERS-CoV in activating cellular and antibody responses in the NALT. Mononuclear cells isolated from adenotonsillar tissues from children and adults were stimulated with ChAdOx1 MERS and heat- or radiation-inactivated MERS-CoV, followed by analysis of anti-MERS IgG antibody and cytokines (IFNγ and TNFα) in cell culture supernatants by ELISA. CD4+ and CD8+ T cell responses, including proliferation and expression of cytokines and cytotoxic molecules were evaluated by flow cytometry. ChAdOx1 MERS induced marked spike-specific anti-MERS IgG antibody responses, which were significantly stronger than those induced by inactivated MERS-CoV. ChAdOx1 MERS also activated higher CD4+ and CD8+ T cell proliferative responses, cytokine expression (IFNγ, TNFα) by CD4+ T cells and cytotoxic perforin and granzyme B expression by CD8+ T cells than by inactivated MERS-CoV. Both antibody and T cell responses were shown stronger in adults than in children. There was a positive correlation between CD4+ T cell proliferation and the antibody response. Human NALT offers an efficient immune induction site for Spike-specific anti-MERS antibody and T cell response. Viral vectored ChAdOx1 MERS induces marked antibody and T cell responses in the NALT, supporting its potential as a mucosal (e.g. intranasal) vaccine against MERS.

Keywords: ChadOx1 MERS; Inactivated-MERS-CoV; MERS-CoV; T cell response; mucosal immunity; nasopharynx-associated lymphoid tissue (NALT); spike-specific antibody.
 
Back
Top Bottom